Tumour functional imaging by PET.

Publication date: Feb 05, 2020

Carcinogenesis is a complex multistep process, characterized by changes at different levels, both genetic and epigenetic, which alter cell metabolism. Positron emission tomography (PET) is a very sensitive image modality that allows to evaluate oncometabolism. PET functionalities are immense, since by labelling a molecule that specifically intervenes in a biochemical regulatory pathway of interest with a positron-emitting radionuclide, we can easily image that pathway. Thus, PET makes possible imaging several metabolic processes and assessing risk prediction, screening, diagnosis, response to therapy, metastization and recurrence. In this paper, we provide an overview of different radiopharmaceuticals developed for PET use in oncology, with a focus on brain tumours, breast cancer, hepatocellular carcinoma, neuroendocrine tumours, bladder cancer and prostate cancer because for these cancer types PET has been shown to be valuable. Most of the described tracers are just used in the research environment, with the aim to assess if these tracers could be able to offer an improvement concerning staging/restaging, characterization and stratification of different types of cancer, as well as therapeutic response assessment. In pursuit of personalized therapy, we briefly discuss the more established metabolic tracers and describe recent work on the development of new radiopharmaceuticals, aware that there will continue to exist diagnostic challenges to face modern cancer medicine.

Abrantes, A.M., Pires, A.S., Monteiro, L., Teixo, R., Neves, A.R., Tavares, N.T., Marques, I.A., and Botelho, M.F. Tumour functional imaging by PET. 06296. 2020 Biochim Biophys Acta Mol Basis Dis.

Concepts Keywords
Biochemical Imaging
Bladder Characterization stratification cancer
Brain Tumours Medicine
Breast Cancer Physical sciences
Cancer Medicinal radiochemistry
Carcinogenesis Natural sciences
Epigenetic Radiopharmaceuticals
Functional Imaging Medical imaging
Genetic Neuroimaging
Hepatocellular Carcinoma Medical physics
Medicine Positron emission tomography
Metabolism Functional imaging
Modality Positron Corporation
Molecule Sandip Basu
Neuroendocrine Radiopharmaceuticals
Oncology Tomography
Positron Emission Tomography


Type Source Name
disease MESH Carcinogenesis
pathway REACTOME Metabolism
disease MESH diagnosis
disease MESH recurrence
pathway KEGG Breast cancer
disease MESH bladder cancer
pathway KEGG Bladder cancer
disease MESH prostate cancer
pathway KEGG Prostate cancer
disease MESH cancer
disease MESH development

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *